Richard Carvajal on Immunotherapy Dosing

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.

The first real-time, non-invasive skin cancer evaluation system has received clearance from the FDA.

Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.

Oncology nurses may play a role in the utilization of artificial intelligence in the clinical setting.

Jeanelle S. King, PA-C, provides an in-depth look at nivolumab-relatlimab in a downloadable reference sheet.